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Abstract
Introduction While current breast cancer chemoprevention
strategies using selective estrogen response modulators and
aromatase inhibitors are quite successful, their effects are
limited to hormonally responsive breast cancer. Hormonally
nonresponsive breast cancer (including estrogen receptor-
negative cancer) is associated with poor prognosis for patients,
and few chemoprevention agents exist for this type of cancer.
The cyclooxygenase-2 inhibitor celecoxib (Celebrex®) is a
nonsteroidal anti-inflammatory drug and as such is a potential
candidate for the prevention of hormonally nonresponsive breast
cancer.
Methods The chemopreventive effects of celecoxib were
evaluated in the neu-induced retroviral rat mammary
carcinogenesis model, to assess the efficacy of celecoxib on
hormonally responsive and hormonally nonresponsive mammary
carcinomas.
Results Dietary celecoxib at 1,200 mg/kg diet was highly
efficacious in the prevention of hormonally responsive mammary
carcinomas in intact rats, decreasing tumor multiplicity by 56%
(P < 0.0001) and by 74% (P = 0.0002) in two independent
experiments. No significant effect was found, however, on
hormonally nonresponsive mammary carcinomas of
ovariectomized rats. Treatment with a combination diet,
consisting of tamoxifen at 2 mg/kg diet and celecoxib at 1,200
mg/kg diet, reduced tumor multiplicity by 72% (P = 0.0002) in
intact rats. This reduction was not statistically different from that
observed with celecoxib alone. Furthermore, long-term
treatment with celecoxib was not associated with reductions in
tumor volume in either intact rats or ovariectomized rats. In
contrast, tamoxifen treatment and the combination regimen
caused significant reductions in tumor volumes in intact rats (P
= 0.01 and P = 0.004, respectively). Consistent with these data,
decreases in proliferation and increases in apoptosis were
detected in tamoxifen-treated and combination diet-treated
tumors. No such modulations were observed in celecoxib-
treated tumors.
Conclusion The chemopreventive effects of celecoxib appear
to be limited to modulations in multiplicity of hormonally
responsive mammary carcinomas. The fact that no synergistic or
additive effects were observed in combination diet-treated rats
raises the question of whether celecoxib is suitable for the
prevention of hormonally nonresponsive breast cancer or for use
in combination therapy with selective estrogen response
modulators or aromatase inhibitors.
Introduction
Although significant advances have been made in the field of
breast cancer prevention, the mortality and morbidity rates for
this disease remain high. This may in part be due to the fact
that most chemoprevention strategies to date (that is, selec-
tive estrogen response modulators (SERMs) and aromatase
inhibitors) target estrogen, and are thus limited in their efficacy
for hormonally responsive breast cancer. Malignancies that do
not respond to hormone ablation therapy (hormonally nonre-
sponsive breast cancers, including estrogen receptor (ER)-
negative tumors) are associated with poor prognosis for the
patient. Efforts therefore need to be concentrated onPage 1 of 9
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subset of tumors.
Cyclooxygenase-2 (COX-2) is an inducible enzyme involved in
prostaglandin synthesis from arachidonic acid and plays a
central role in inflammation. COX-2 overexpression is suffi-
cient to induce tumorigenesis of mammary cancer [1] and its
inhibition is thought to be the principle mechanism for cancer
prevention by nonsteroidal anti-inflammatory drugs [2]. While
COX-2 expression is virtually absent from normal mammary
parenchyma, its overexpression is observed in roughly one-
third of human breast cancers [3]. In her-2/neu-positive
lesions, COX-2 overexpression is even more frequent and was
observed in 43% of invasive breast carcinomas and in as many
as 63% in ductal carcinomas in situ [4].
The COX-2 selective inhibitor celecoxib has been shown in
preclinical studies to prevent hormonally responsive mammary
tumors in carcinogen-induced rat models [5-7]. In addition,
there is evidence that celecoxib prevents mammary tumors in
transgenic mice [8,9] and in a human xenograft model [10],
both of which are ER-negative models and are therefore con-
sidered hormonally nonresponsive.
The best documented mechanism for cancer prevention with
celecoxib involves the downregulation of local estrogen bio-
synthesis by aromatase enzyme Cyp19. Both in vitro data
[11,12] and in vivo data [13] show that COX-2 inhibition is
associated with prostaglandin E2 reduction and suppression
of aromatase activity. Furthermore, there is evidence that the
nonselective nonsteroidal anti-inflammatory drug aspirin is effi-
cacious for the prevention of hormone receptor-positive (ER-
positive and progesterone receptor-positive) breast cancer
but not hormone receptor-negative breast cancer [14]. These
data combined suggest that one mechanism by which
celecoxib prevents mammary cancer is through reductions in
estrogen, which would limit its preventive potential to hormo-
nally responsive tumors.
We investigated this estrogen reduction hypothesis using the
neu-induced retroviral rat mammary carcinogenesis model
[15]. This chemoprevention model offers two distinct hormo-
nal configurations, intact and ovariectomized. The intact model
produces both hormonally responsive and hormonally nonre-
sponsive mammary carcinomas. The SERM tamoxifen gener-
ally causes a 50% reduction in tumor multiplicity in intact rats
[15], which is similar to its efficacy in women [16]. In ovariect-
omized rats, all of the mammary carcinomas that develop are
hormonally nonresponsive. Molecularly, this hormonal nonre-
sponsiveness is characterized by reductions >75% in ER lev-
els and reductions of nearly 90% in PR levels, as quantified
using a cytosolic receptor-binding assay [17]. Prevention
strategies using tamoxifen are not efficacious for these tumors.
The experiments presented in the current manuscript chiefly
address the questions of whether celecoxib is suitable for the
prevention of hormonally nonresponsive mammary carcinomas
and whether the preventive effects of celecoxib extend beyond
those of the SERM tamoxifen.
Materials and methods
Chemoprevention in neu-induced rats
All animal experiments were performed at our facility under
protocols approved by the University of Wisconsin Medical
School Animal Care and Use Committee. Virgin Wistar–Furth
female rats were obtained from Harlan Sprague–Dawley
(Madison, WI, USA) at 6 weeks of age. All rats were group
housed in suspended wire cages and were maintained in a
light/dark cycle of 12 hours, receiving Teklad lab meal (#8604,
Teklad, Madison, WI, USA) and acidified water ad libitum.
After 1–2 weeks of acclimation, at approximately 50–60 days
of age, all rats underwent retroviral infusion with the pJRneu
vector, which induces mammary carcinogenesis by expressing
the activated her2/neu oncogene. The construction and gen-
eration of the pJRneu retroviral vector have been previously
described [18,19]. Details on retroviral gene transfer into the
mammary epithelium of the laboratory rat [20] and the applica-
tion of this technology for chemoprevention in the neu-induced
retroviral rat carcinogenesis model [15] have also been pub-
lished previously. In brief, a suspension of replication-defective
amphotropic retrovirus containing the activated neu oncogene
was infused into the central ducts of the 12 rat mammary
glands. The rats for the intact model were infused with viral tit-
ers of 1 × 105 clone-forming units (CFU)/ml and 7.5 × 104
CFU/ml (Experiments 1a and 2a, respectively), and were left
intact. The animals for the ovariectomized model received viral
titers of 5 × 105 CFU/ml and 1 × 105 CFU/ml (Experiments 1b
and 2b, respectively), and underwent a bilateral ovariectomy 2
days after the infusion.
At 4 days post infusion, the rats were randomly assigned to the
treatment groups and the experimental diets were started. All
animals were weighed and palpated for mammary tumors
weekly. The studies were terminated 12 weeks post infusion
for intact animals and 18 weeks post infusion for ovariect-
omized rats. At necropsy, the total number of carcinomas, the
mammary gland locations, and the size of each mammary car-
cinoma were recorded. A minimal size criterion of 3 mm in the
largest two dimensions of each mammary carcinoma was
applied in order to be included in the analysis. Tumor volumes
were calculated from three-dimensional measurements using
the formula: volume = 0.5 × length × width × height.
Chemopreventive agents
Tamoxifen was purchased from Sigma (St Louis, MI, USA) and
celecoxib (LKT Laboratories, Inc., St Paul, MI, USA) was
obtained through the NCI Division of Cancer Prevention
Repository (Rockville, MD, USA). All experimental diets werePage 2 of 9
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USA), which was also used as the control diet. Dietary
tamoxifen was prepared as 2 mg/kg diet and celecoxib as
1,200 mg/kg diet. The combination diet contained full doses
of both compounds. All diets were prepared fresh weekly,
stored at -20°C and were fed daily.
Proliferation and apoptosis
Upon necropsy, mammary carcinomas from Experiment 2
were collected, fixed and paraffin-embedded. Consecutive
slices were stained with H & E for histological evaluation or
were used for proliferation and apoptosis assays.
The proliferation index of mammary carcinomas was evaluated
by KI-67 staining [21,22]. Immunohistochemical procedures
were performed according to standard protocols using VP-
K452 (Vector Labs, Burlingame, CA, USA) as the KI-67 pri-
mary antibody. Primary antibody binding was visualized by
horseradish peroxidase-conjugated secondary antibody, the
VECTASTAIN® avidin–biotinylated enzyme complex Elite Sys-
tem (Vector Labs) and diaminobenzidine as the chromogen.
The apoptotic index of mammary carcinomas was evaluated by
terminal deoxynucleotidyl transferase-mediated nick end-labe-
ling [23] using the TdT-FragEL™ DNA Fragmentation Detec-
tion Kit QIA 33 (Calbiochem, Darmstadt, Germany). Slides
were processed according to the manufacturer's recommen-
dations. Approximately 1,000 cells per tumor in several ran-
dom fields were evaluated by light microscopy for proliferating
or apoptotic cells.
Tissue generation for the quantitative real-time PCR 
assay
Fully differentiated mammary carcinomas from the control diet
group of Experiment 1a, which had previously been flash fro-
zen and stored at -80°C, were used for the mammary carci-
noma tissue group.
For the mammary gland and ductal carcinoma in situ tissue
groups, 6-week-old Wistar–Furth virgin female rats were
obtained from Harlan Sprague–Dawley. The rats were initially
housed and treated the same as the animals used in the pre-
vention experiments. Rats designated for mammary gland tis-
sues were housed in our animal facility until 9 weeks of age,
when they were sacrificed. Lower abdominal and upper
inguinal mammary glands were excised, flash frozen and
stored at -80°C. Rats designated for in situ carcinoma tissue
groups underwent retroviral infusion with the pJRneu vector at
7 weeks of age. A high viral titer of 1 × 107 CFU/ml was used
to insure a high density of in situ carcinomas within the ductal
tree structure of the lower abdominal mammary glands.
Two days post infusion a subset of the rats underwent a bilat-
eral ovariectomy. At 15 days post infusion all rats were sacri-
ficed. In situ carcinoma containing portions, distal to the lymph
nodes within the lower abdominal mammary glands, were
excised, flash frozen and stored at -80°C.
Quantitative real-time PCR assay
Expression of COX-2 was measured by quantitative real-time
PCR. Rat mammary glands, mammary carcinomas and mam-
mary glands containing in situ carcinomas were homogenized
in Tri-Reagent (Molecular Research Center, Inc., Cincinnati,
OH, USA) using a Polytron tissue homogenizer. Whole RNA
was extracted using a MagMAX™-96 for Microarrays Total
RNA Isolation Kit (Ambion, Inc., Austin, TX, USA), following the
manufacturer's directions. RNA was quantified using a ND-
1000 Spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE, USA) and was reverse-transcribed using the Super-
Script® II Reverse Transcriptase Kit (Invitrogen, Carlsbad, CA,
USA) following the manufacturer's instructions.
The rat COX-2 specific forward (GCTGATGACT-
GCCCAACTC) and reverse (CGGGATGAACTCTCTC-
CTCA) primers were designed using Primer3 software [24].
Expression levels of acidic ribosomal phosphoprotein PO
36B4 have been shown to be estradiol independent [25], and
the rat 36B4 transcript was used as the endogenous control
using forward (AGCTTTGGGCATCACCACTA) and reverse
(CTCCCACCTTGTCTCCAGTC) primers. Quantitative real-
time PCR was performed using a SYBR® Green PCR Master
Mix Kit (Applied Biosystems, Foster City, CA, USA) on a
7900HT Sequence Detector (Applied Biosystems) under
default PCR conditions.
Data analyses were performed using SDS 2.2 software
(Applied Biosystems). The cycle threshold (CT) values were
determined at a manual threshold at which all real-time curves
were in he exponential doubling phase. Technical replicates
were averaged and the COX-2 expression values were nor-
malized against endogenous control 36B4 expression values.
Average COX-2 transcript concentrations were calculated for
all tissues groups. The fold changes in COX-2 expression for
mammary carcinoma and in situ carcinomas tissue groups
were reported relative to mammary gland baseline expression.
Statistical analysis
The number of carcinomas per animal at necropsy was mod-
eled using generalized linear models assuming Poisson and
binomial link functions. Differences due to diets were
assessed by comparing the change in scaled deviance due to
diet with the appropriate chi-squared distribution. If an overall
significant effect of diet was found, each diet was compared
with the control diet individually using a similar procedure.
The tumor volume, as a cubed dimension parameter, repre-
sents a skewed distribution in which very large tumors contrib-
ute disproportionately to the group averages. A Box–Cox
transformation was performed [26], converting the raw tumor
volumes into log10-transformed values. The log10-transformedPage 3 of 9
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performed to obtain the P values for differences in tumor
volume.
Statistical analysis for final body weight and for proliferation
and apoptosis assays were performed by the Wilcoxon rank-
sum (Mann–Whitney) test.
For the quantitative real-time PCR measurements, the mean
CT values were calculated across technical duplicates. In each
tissue group, the difference between COX-2 CT values and
endogenous control 36B4 CT values were determined for 12
individual samples. A two-sided t test was used to determine
the P values for each tissue group compared with the mam-
mary gland group.
Results
Effects of tamoxifen, celecoxib and the combination 
regimen on tumor multiplicity
In the neu-induced rat mammary carcinogenesis model,
approximately 50% of mammary carcinomas in the intact
model are hormonally responsive and can therefore be pre-
vented by tamoxifen (2 mg/kg diet) treatment. In two inde-
pendent experiments using the intact model, the average
number of mammary carcinomas developing per rat following
tamoxifen treatment was decreased by 49% (P < 0.0001,
Table 1 and Figure 1a) and by 33% (P = 0.1, Table 1 and Fig-
ure 1c), respectively. While the latter result did not reach sta-
tistical significance, there was a clear trend toward decreased
tumor multiplicity throughout the course of the prevention
experiment. In the ovariectomized model, where tumors are
hormonally nonresponsive, tamoxifen treatment had no signifi-
cant effect on tumor multiplicity compared with the control
groups (Table 1 and Figure 1b,d).
Celecoxib treatment was efficacious for the prevention of
intact neu-induced rat mammary carcinomas, reducing tumor
multiplicity in two independent trials by 56% (P < 0.0001,
Table 1 and Figure 1a) and by 74% (P = 0.0003, Table 1 and
Figure 1c). In ovariectomized rats, however, no significant
reductions of tumor multiplicity were observed with celecoxib
treatment (Table 1 and Figure 1b,d).
Regimens combining tamoxifen and celecoxib caused a signif-
icant reduction in tumor multiplicity in intact rats and generally
paralleled the response caused by celecoxib treatment (P =
0.0003, Table 1 and Figure 1c). Similarly to tamoxifen and
celecoxib individual treatments, the combination diet did not
alter tumor multiplicity in ovariectomized rats.
Effects of tamoxifen, celecoxib and the combination 
regimen on tumor volume
In two independent experiments, the administration of dietary
tamoxifen caused significant decreases in the tumor volume in
intact rats (P = 0.03 and P = 0.01, Table 1). No such effect
was observed in ovariectomized rats.
Interestingly, celecoxib treatment did not reduce the tumor vol-
ume in either intact rats or ovariectomized rats. Indeed, a sig-
nificant increase in tumor volume was seen in mammary
carcinomas of ovariectomized rats following celecoxib treat-
ment in Experiment 2b (P = 0.03, Table 1).
Similarly to tamoxifen-treated rats, treatment with the combina-
tion diet caused a significant decrease of the tumor volume in
intact rats (P = 0.004, Table 1), while having no effect in ova-
riectomized animals.
Effects of tamoxifen, celecoxib and the combination 
regimen on body weight gain
Tamoxifen treatment caused reductions in the final body
weight of 12% in intact rats for Experiments 1a and 2a (P <
0.0001 and P < 0.0001, Table 1). This reduction was more
pronounced in ovariectomized animals, where tamoxifen
administration led to decreases in final body weight of 29%
and of 28% in Experiments 1b and 2b (P < 0.0001 and P <
0.0001, Table 1), respectively.
In contrast, celecoxib treatment did not cause significant
reduction in body weight gain in intact rats or ovariectomized
rats (Table 1). Combination diet administration caused signifi-
cant decreases in final body weights of 15% (P < 0.0001,
Table 1) in intact rats and of 30% (P < 0.0001, Table 1) in ova-
riectomized animals, similar to those observed with tamoxifen
treatment alone.
Histopathological analysis
Histopathological evaluation of H & E-stained tumor sections
classified all tumors as mammary carcinomas. No systematic
morphological differences were associated with chemopre-
vention using tamoxifen, celecoxib or the combination
regimen.
Effects of tamoxifen, celecoxib and the combination 
regimen on proliferation and apoptosis in neu-induced 
mammary carcinomas
The long-term administration of tamoxifen resulted in a statisti-
cally significant reduction of the proliferation rate from 14.8%
to 7.8% in intact rats (P = 0.004, Figure 2a). No such trend
was observed for tumors from ovariectomized animals (Figure
2b). Tamoxifen treatment increased the apoptotic index of the
neu-induced mammary carcinomas from 0.7% to 1.9% (P =
0.0008, Figure 2c) in intact rats. In the ovariectomized animals
there was no measurable difference in the rate of apoptosis
between control rats and tamoxifen-treated rats (Figure 2d).
Celecoxib treatment had no significant effect on the rates of
proliferation or apoptosis of mammary carcinomas from either
intact rats or ovariectomized rats (Figure 2).Page 4 of 9
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eration of neu-induced mammary carcinomas in intact rats
from 14.8% to 7.0% (P = 0.001, Figure 2a). The combination
regimen also increased the apoptotic index from 0.7% to 2.2%
(P = 0.0005, Figure 2c) in mammary carcinomas from intact
rats. In mammary carcinomas from ovariectomized animals, the
combination treatment did not modulate the rate of prolifera-
tion or apoptosis significantly (Figure 2b,d).
Cyclooxygenase-2 mRNA expression in mammary gland, 
mammary carcinomas and in situ carcinomas
COX-2 mRNA expression, as measured by quantitative real-
time PCR assay, was lowest in normal mammary gland tissue,
which was used as baseline expression and to which the
COX-2 transcript levels of other tissues were compared. Fully
differentiated mammary carcinomas in intact rats exhibited a
mean 2.0-fold increased (P = 0.02) COX-2 mRNA expression
(Figure 3). The COX-2 expression in in situ carcinomas of
intact rats and ovariectomized rats was 3.1-fold and 4.9-fold
increased (P = 0.0003 and P = 0.002, Figure 3), respectively.
The difference between COX-2 expression in in situ carcino-
mas of intact rats and ovariectomized rats was not statistically
different.
Discussion
The chemopreventive effects of celecoxib appear to be limited
to hormonally responsive mammary carcinomas in the neu-
induced retroviral mammary carcinogenesis rat model. In two
chemoprevention experiments with different control tumor
multiplicities, celecoxib treatment proved ineffective in
Figure 1
Modulation of tumor multiplicity during treatment with tamoxifen and celecoxib alone and in combinationl tion of tumor mult plicity during treatment with tamoxifen and celec xib alone and in combination. Efficacies of (a, b) tamoxifen or 
celecoxib alone and (c, d) tamoxifen, celecoxib or combination treatment to prevent the development of mammary carcinomas in (a, c) intact rats and 
(b, d) ovariectomized rats. Tumor multiplicity curves labeled with the average number of mammary carcinomas per rat at the date of necropsy.Page 5 of 9
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with celecoxib is dependent on an intact estrogen and proges-
terone milieu in this model.
Celecoxib's efficacy in intact neu-induced rats is inversely cor-
related to the control tumor multiplicity of the experiment,
which, in our model, is a function of the retroviral titer. In a pre-
vious experiment in which the control animals had nearly 10
carcinomas per rat, celecoxib was not efficacious (data not
shown). In the present Experiment 1a, however, it decreased
tumor multiplicity by 50% at a control tumor multiplicity of
seven carcinomas per rat. In Experiment 2, we further
decreased the retroviral titer to evaluate whether this corre-
lates with a greater chemopreventive effect of celecoxib.
Indeed, at a very low control tumor multiplicity of less than
three carcinomas per rat, celecoxib treatment resulted in a
74% reduction in tumor multiplicity.
The intact neu-induced retroviral rat model approximates the
hormone responsiveness of breast cancer women. Similar to
the 50% reductions in tumor multiplicity in tamoxifen-treated
intact rats, the National Surgeon Adjuvant Breast and Bowel
Project Breast Cancer Prevention Trial 1 concluded a 50%
overall reduction of invasive breast cancer in women receiving
tamoxifen [16]. The trial also estimated that about 70% of
human breast cancers express ERα and therefore possess the
potential to respond to hormone ablation therapy. In intact rats,
in which both hormonally responsive and hormonally nonre-
sponsive carcinomas arise, celecoxib treatment was associ-
ated with reductions of tumor multiplicity of 56% and 74%. It
is therefore possible that tamoxifen and celecoxib both act on
an overlapping subset of tumors, but celecoxib does so in a
more comprehensive fashion, especially during conditions of
optimized control tumor multiplicities. This hypothesis is also
supported by the highly similar tumor multiplicities observed in
intact rats treated with either celecoxib alone or with a combi-
nation diet.
The tumor volume, a measurement of the tumor growth rate,
was modulated in intact rats by tamoxifen treatment and com-
bination treatment, but not by celecoxib treatment. Mechanis-
tically, these findings are supported by downregulation of
Table 1
Chemopreventive effects of tamoxifen and celecoxib alone and in combination on tumor multiplicity, tumor volume and final body 
weights
Experiment Intact/ovariectomized rat 
viral titer
Number of rats Treatment Tumor multiplicity 
(carcinomas/rat)
Tumor volumea, log10 
(mean) (mm3)
Final body weight (g)
1ab Intact, 1 × 105 CFU/ml 15 Control 7.0 ± 0.9 1.86 ± 0.06 (201) 208 ± 4.9
15 Tamoxifen 3.6 ± 0.8, P < 0.0001 1.68 ± 0.07 (101), 
P = 0.03
184 ± 2.9, 
P < 0.0001
15 Celecoxib 3.1 ± 0.8, P < 0.0001 1.96 ± 0.10 (444), ns 199 ± 2.9, ns
2a Intact, 7.5 × 104 CFU/ml 14 Control 2.8 ± 0.7 2.16 ± 0.11 (433) 212 ± 2.3
15 Tamoxifen 1.9 ± 0.8, ns 1.72 ± 0.13 (179), 
P = 0.01
186 ± 1.9, 
P < 0.0001
13 Celecoxib 0.7 ± 0.2, P = 0.0002 1.98 ± 0.27 (438), ns 205 ± 2.7, ns
14 Combination 0.8 ± 0.3, P = 0.0002 1.45 ± 0.18 (67), 
P = 0.004
181 ± 2.2, 
P < 0.0001
1bb Ovariectomized, 
5 × 105 CFU/ml
24 Control 3.7 ± 0.5 1.76 ± 0.08 (229) 261 ± 5.0
25 Tamoxifen 3.3 ± 0.6, ns 1.77 ± 0.07 (207), ns 186 ± 2.0, 
P < 0.0001
25 Celecoxib 3.3 ± 0.5, ns 1.84 ± 0.07 (511), ns 257 ± 2.3, ns
2b Ovariectomized, 
1 × 105 CFU/ml
25 Control 1.2 ± 0.2 1.60 ± 0.10 (88) 262 ± 3.1
25 Tamoxifen 1.3 ± 0.2, ns 1.64 ± 0.12 (167), ns 188 ± 2.2, 
P < 0.0001
23 Celecoxib 1.4 ± 0.3, ns 1.98 ± 0.11 (272), 
P = 0.03
250 ± 3.0, ns
24 Combination 1.4 ± 0.5, ns 1.68 ± 0.10 (107), ns 182 ± 1.7, 
P < 0.0001
Mean values and standard errors of the means are indicated for tumor multiplicity, tumor volume and final body weights. CFU, clone-forming units. 
P values are indicated for the difference between the control and treatments for all measured parameters; ns, no significant difference. aCalculated 
from three-dimensional measurements using the formula: volume = 0.5 × length × width × height. Data normalized by log10 transformation. 
bControl and tamoxifen treatment groups have been published previously [15].Page 6 of 9
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treatments with tamoxifen and with the combination regimen.
Celecoxib alone caused no such changes in neu-induced
mammary carcinomas of intact rats or ovariectomized rats. The
fact that celecoxib reduced tumor multiplicity but, unlike
tamoxifen, failed to modulate tumor growth rates suggests a
distinct mechanistic difference in the chemopreventive effects
of those compounds. It should be noted that proliferation and
apoptosis analysis was performed on long-term treated
tumors and serves only to explain differences in the final tumor
volume, and not as a measure of the prevention mechanism.
Consistent with the chemopreventive effects on hormonally
responsive mammary carcinomas observed in our model,
celecoxib has been shown highly efficacious for the prevention
of mammary cancer in chemically induced rat models. Two
different groups using 9,10-dimethylbenz-a-anthracene as the
carcinogen in rats reported reductions in tumor multiplicity of
69% and of 86% associated with celecoxib administration at
a dose of 1,500 ppm [5,6]. This effect is more dramatic than
that observed in our model. In the 9,10-dimethylbenz-a-anthra-
cene model, however, almost all tumors are hormonally
responsive, resulting in prevention rates of >85% tumor multi-
plicity with tamoxifen treatment or ovariectomy [27]. The mod-
ulation of the tumor volume appears less consistent. While our
finding that the tumor volume is not reduced with celecoxib
treatment is substantiated in one study using the 9,10-dimeth-
ylbenz-a-anthracene rat model [6], another study reported an
Figure 2
Modulation of proliferation and apoptotic indices during tamoxifen and celecoxib treatment alone and in combinationl tion of proliferation and a optotic indices during tamoxifen and celecoxib treatment lone and in combination. The proliferation index 
was measured by KI-67 expression in neu-induced mammary carcinomas from (a) intact rats and (b) ovariectomized rats. The terminal deoxynucle-
otidyl transferase-mediated nick end-labeling assay was performed to asses the apoptotic index in (c) intact rats and (d) ovariectomized rats. Ten 
mammary carcinomas were evaluated per treatment group. Approximately 1,000 cells were scored in each tumor. Labeled bars indicate means. *P 
< 0.005, **P < 0.001.Page 7 of 9
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1,500 ppm [5].
Mammary tumors are ER-negative in mouse mammary tumor
virus-neu transgenic mice, and therefore tend to be hormonally
nonresponsive tumors. In contrast to our findings that
celecoxib did not reduce tumor multiplicity of hormonally non-
responsive mammary carcinomas, tumor multiplicity was
reduced by 41% in mouse mammary tumor virus-neu trans-
genic mice at a dose of 900 ppm [9]. This result should be
understood in context, however, because tamoxifen treatment
also has been shown to significantly decrease tumor multiplic-
ity in this preclinical model [28]. Interestingly, no reductions in
tumor volume were observed in celecoxib-treated mouse
mammary tumor virus-neu transgenic mice [9]. This is
consistent with our finding that celecoxib treatment does not
modulate tumor volume in hormonally nonresponsive mam-
mary carcinomas.
In a recent publication, the preventive effects of celecoxib on
ER-positive and ER-negative breast cancers were investigated
in a human xenograft mouse model [10]. Similar to our find-
ings, proliferation as measured by Ki-67 expression was not
modulated by celecoxib in either ER-positive or ER-negative
xenografts. These experiments did, however, reveal a
celecoxib-mediated increase in apoptosis, as measured by the
terminal deoxynucleotidyl transferase-mediated nick end-labe-
ling assay, in ER-positive xenografts only.
Importantly, no significant reductions in body weights were
observed in celecoxib-treated animals. In contrast, tamoxifen
treatment is associated with significant reductions in body
weight gain in both intact and ovariectomized models at phys-
iologically active doses. Although the utilized dose of
tamoxifen caused decreases in the final body weight, the dose
is nontoxic in the sense that doses of tamoxifen 50 times
greater (100 ppm) did not cause lethality in intact rats (R.A.
Lubet, unpublished data). Interestingly, even though tamoxifen
treatment had a greater effect on the body weights of ovariec-
tomized rats, this was not associated with a reduction in tumor
multiplicity compared with control rats.
In general, COX-2 expression in the neu-induced retroviral
mammary carcinogenesis rat models recapitulates the expres-
sion patterns observed in women. While rat mammary gland
tissue expresses COX-2 at very low baseline levels, COX-2
overexpression is observed in mammary carcinomas and, to an
even greater degree, in in situ carcinomas. This is consistent
with the observation that COX-2 is not expressed in normal
breast tissue but is overexpressed in 43% of her-2/neu-posi-
tive invasive breast carcinomas and in 63% of ductal carcino-
mas in situ [4].
Importantly, COX-2 is expressed in in situ carcinomas of ova-
riectomized rats in our model. The fact that celecoxib does not
prevent mammary carcinomas in ovariectomized rats therefore
appears to be independent of the COX-2 expression in these
tissues.
The present observations are consistent with a mechanism by
which celecoxib prevents mammary cancer through reduc-
tions in estrogen, limiting its preventive potential to hormonally
responsive tumors.
Conclusion
Overall, our data indicate that chemoprevention with celecoxib
is limited to hormonally responsive mammary carcinomas and
that this compound does not modulate the tumor volume in our
model. The fact that no synergistic or additive effects were
observed in combination diet-treated rats raises the question
of whether celecoxib is suitable for the prevention of hormo-
nally nonresponsive breast cancer or for use in combination
therapy with SERMs or aromatase inhibitors. While selective
cyclooxygenase-2 inhibitors might be generally thought a non-
endocrine alternative to SERMs or aromatase inhibitors, we
provided preclinical evidence that this might be an incomplete
assessment that warrants further investigation.
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